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Abstract
Background: The forkhead box transcription factor FOXQ1 has been shown to be upregulated in colorectal cancer (CRC)
and metastatic breast cancer and involved in tumor development, epithelial-mesenchymal transition and chemoresistance.
Yet, its transcriptional regulation is still unknown.
Methods: FOXQ1 mRNA and protein expression were analysed in a panel of CRC cell lines, and laser micro-dissected human
biopsy samples by qRT-PCR, microarray GeneChipH U133 Plus 2.0 and western blots. FOXQ1 regulation was assayed by
chromatin immunoprecipitation and luciferase reporter assays.
Results: FOXQ1 was robustly induced in CRC compared to other tumors, but had no predictive value with regards to grade,
metastasis and survival in CRC. Prototype-based gene coexpression and gene set enrichment analysis showed a significant
association between FOXQ1 and the Wnt pathway in tumors and cancer cell lines from different tissues. In vitro experiments
confirmed, on a molecular level, FOXQ1 as a direct Wnt target. Analysis of known Wnt targets identified FOXQ1 as the most
suitable marker for canonical Wnt activation across a wide panel of cell lines derived from different tissues.
Conclusions: Our data show that FOXQ1 is one of the most over-expressed genes in CRC and a direct target of the canonical
Wnt pathway. It is a potential new marker for detection of early CRC and Wnt activation in tumors of different origins.
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Introduction
The canonical Wnt pathway plays an important role in
embryogenesis and cancer development [1]. The hallmark of
Wnt activation is the nuclear accumulation of its main effecter
molecule b-catenin. In the nucleus, b-catenin is a component of
the transcriptional activation complex that includes members of
the TCF/LEF family of DNA binding proteins [2,3].
Wnt has been shown to contribute to cancer progression in a
variety of tumors [4]. Most evident is the role of Wnt signalling in
colorectal cancer (CRC) [5]. Here mutational activation of the
Wnt pathway is considered the initiating event and is required for
the formation of tumors [5]. Familial adenomatous polyposis is a
hereditary condition where the APC gene is mutated, which
directly leads to increased Wnt activity. Patients with these
mutations develop CRC at an early age if not treated [6]. About
85% of all sporadic and hereditary colorectal tumors show loss of
APC function [2]. Among the 15% of CRCs that retain wildtype
APC, point mutations were found in ß-catenin which change any
of the four serine/threonine residues in its N terminus, the putative
targets of GSK-3 [5]. Recent findings by the Cancer Genomic
Atlas Network suggest that 93% of CRCs have an altered Wnt
signaling pathway [7]. Sixteen different genes involved in Wnt
signaling were found to be altered with APC and ß-catenin being
the most frequent [7]. In breast, lung and prostate cancer Wnt
activity has been linked to an increased risk of metastasis, cancer
stem cell properties and to induce epithelial to mesenchymal
transition (EMT) [8–11].
Identified in 1998 in mouse the transcription factor forkhead
box Q1 (Foxq1) was shown to be responsible for a defect in hair
follicle development in the satin mouse strain [12–14]. Through
analysis of knockout mice Foxq1 has been shown to play a role in
gastric acid secretion and mucin gene expression [15,16].
Recently, it was shown that FOXQ1 increased tumorigenesis of
colon and breast cancer cells. FOXQ1 was upregulated in CRC
and in metastatic breast cancer cell lines, and could protect lung,
breast and colon cancer cell lines from chemotherapy induced
apoptosis and regulate EMT in CRC and breast cancer cell lines
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[17–19]. The mechanisms regulating FOXQ1 expression in CRC
and metastatic breast cancer cell lines have not been examined.
Reports have indicated that FOXQ1 is a downstream mediator of
Hoxa1 and TGFß signalling pathways, but no molecular evidence
exists for a direct regulation [19,20], nor has in-depth analysis
been done of genes and pathways associated with FOXQ1.
Through the use of public available expression data sets we have
examined the expression of FOXQ1 in solid tumors and cancer
cell lines. We show that FOXQ1 is one of most upregulated genes
in CRC, however, the level of expression was not associated with
metastasis, stage or grade. For the first time we demonstrate that
FOXQ1 is a direct Wnt target and the expression level correlates
with the overall expression of Wnt genes in cancer biopsies and cell
lines, thus, demonstrating its potential as a marker for Wnt
activation.
Materials and Methods
Cell lines
The epithelial cell lines SW480, SW620 and COLO320 were
cultured in RPMI 1640 containing 10% fetal calf serum (FCS),
MDA-MB-231, HT29, LS174T and HEK293T in Dulbecco’s
modified Eagle essential medium (DMEM) Glutamax containing
10% FCS, Caco-2 were cultured in DMEM Glutamax, 10% FCS
supplemented with 1% NEAA, T84 in RPMI 1640 containing
10% FCS and 2 mM glutamine, and HCT116 (generously
provided by Dr. M. Aguet at the ISREC/EPFL, Switzerland) in
McCoys medium containing 10% FCS [21]. All of the cell lines
were obtained from LGC Standards (LGC Standards, France) if
not stated otherwise. Primary fibroblasts were cultured in DMEM
Glutamax supplemented with 10% FCS, 5 mL penicillin/strepto-
mycin and 0.5 mL gentamycin [21]. Caco-2 CDX2 knock-down
cells were a generous gift from Drs. Felsani and Natoli (CNR,
Italy). All cell lines were cultured at 37uC and 5% CO2.
Reporter plasmids
The human FOXQ1 promoter region was amplified from
MDA-MB-231 human breast cancer cells. The resulting 2.5 kb
wildtype amplicon was cloned into the pGL3-Basic vector
(Promega, Germany) producing pGL3-FOXQ1_WT. Mutation
of the TCF4 binding site was done by site-directed mutagenesis
thus generating (Strategene, Germany) pGL3-FOXQ1_MUT.
Information about primers is presented in Table S1.
Wnt activation and luciferase reporter assay
The Wnt pathway was activated in HEK293 and HCT116 cells
via introduction of a constitutively active form of ß-catenin
harbouring mutations in the GSK-3 recognition site (pcDNA3-
S33Y, Addgene plasmid 19286) [22] or by inhibiting GSK-3
activity by lithium chloride (LiCl, Sigma-Aldrich) treatment
[23,24]. Briefly, cells were treated with LiCl at a final concentra-
tion of 20 mM for 24 hours and analysed, or cells were transfected
with pcDNA3-S33Y using Lipofectamine 2000 (Invitrogen,
Germany) according to manufactures protocol, selected with
600 mg/mL G418 and analysed.
Luciferase reporter assay was carried out according to
manufacturer’s protocol. Briefly, HEK293 and HCT116 cells
were transfected with pRL-TK as control for transfection
efficiency (Promega, Germany) and one of the FOXQ1 promoter
constructs (pGL3-FOXQ1_WT, pGL3-FOXQ1_Mut or pGL3-
Emtpy) using Lipofectamine 2000 (Invitrogen, Germany). The
Wnt pathway was activated as described above and cells were
analysed for renilla luciferase and firefly luciferase activity
48 hours after transfection by measuring bioluminescence on a
Synergy HT (BioTek, Winooski, Vermont USA) using Dual-Glo
(Promega, Germany). Data is represented as firefly luciferase
activity normalized to renilla luciferase activity.
Quantitative real-time PCR
Total RNA was extracted using Nucleo-Spin RNA-extraction
kit from Machery-Nagel (Oensingen, Switzerland). Reverse
transcription of RNA to cDNA was done using M-MLV
(Promega, Switzerland). Quantitative real-time PCR (qRT-PCR)
was performed using SYBR-Green PCR assay (Applied Biosys-
tems, Switzerland) on ABI 7900 machine (Applied Biosystems,
Switzerland), with the following thermal cycling condition: 2 min
at 50uC, 10 min at 95uC followed by 40 cycles at 95uC for 15 s
and 60uC for 1 min. Primer sequences are listed in Table S1. All
biological samples were measured in triplicates and the resulting
data were normalized to H3.
Western blot analysis
For immunoblotting cells were lysed in laemmli buffer and
protein concentration was determined using BCA protein assay kit
(Pierce, Germany). 30 mg protein was loaded per sample and
resolved on a 8% polyacrylamide–SDS gels and transferred onto
nitrocellulose membranes, which were immediately blocked with
2% BSA for 1 h. Membranes were then probed with antibodies
against FOXQ1 (Sigma, AV33747). GAPDH (Santa Cruz
Biotechnology, SC-25778) or Tubulin (Santa Cruz Biotechnology,
Santa Cruz, USA, SC-52586) were used a loading control. Blots
were developed using peroxidise-conjugated secondary antibodies,
and chemiluminescence system (Thermo Scientific, Germany).
Chromatin immune precipitation
SW480 cells were cross-linked with 1% formaldehyde in PBS
for 10 min at room temperature and the fixation was stopped by
adding glycine at a final concentration of 0.125 M. Pelleted cells
were resuspended and sonicated to produce DNA fragments with
a size of ,1000 bp (input). Samples were immunoprecipitated
overnight at 4uC using 3 mg of ß-catenin antibody (BD
Transduction Laboratories, 610154) or negative control antibody
(Upstate Millipore, catalogue# 12-371, Switzerland) and protein-
A magnetic beads (Upstate, Millipore, catalogue# 16-611,
Switzerland). Antibody-chromatin complexes were washed, eluted
and crosslinking was reversed in 10% SDS, 1 M NaHCO3, NaCl
5 M for 5 hours at 65uC. Antibodies and beads were separated in
EDTA 0.5 M, TrisHCl 1 M pH 6.5, protein kinase K at 45uC for
2 hours and at 95uC for 10 minutes. DNA was recovered and
purified. The immunoprecipitated DNA was quantified by qRT-
PCR. The amount of immunoprecipitated DNA was calculated in
reference to a DNA standard curve and normalized to input and
GAPDH control for each experiment. Primer sequences are listed
in Table S1.
Lentiviral production and transduction
SW480 and HEK293T cells were transduced with lentiviral
particles carrying short hairpin RNAs targeting FOXQ1
(shFOXQ1mir) or the Wnt sensitive reporter construct 7TGC
(Addgene plasmid 24304) [25]. Lentiviral particles were produced
in 293FT cells (Invitrogen, Switzerland), cotransfected with
lentiviral vector and packaging vectors. Lipofectamine 2000
(Invitrogen, Switzerland) was used as transfection reagent.
293FT cells were grown in DMEM media supplemented with
10% FCS and non-essential amino acids (Invitrogen, Switzerland).
For transfection, 30 mg of DNA was diluted in 1.5 mL Opti-MEM
(Invitrogen, Switzerland) with a ratio of 4:3:1 of transfer vector
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(shFOXQ1 or 7TGC), packaging coding vector (pCMV-dR8.74)
and envelope coding vector (pMD2.G). 30 mL of Lipofectamine
2000 was diluted in 1.5 mL of Opti-MEM. The two solutions were
combined following 5 min incubation at room temperature. The
resulting mixture was added to 293FT cells after 1 hour of
incubation at room temperature. 16 hours after transfection the
media was changed to RPMI with 10% FCS. 40 and 64 hours
after transfection of 293FT cells the viral supernatants were
collected and centrifuged at 2006 g for 5 minutes, and filtered
through a sterile 0.45 mm syringe filter (Millipore, Switzerland).
The viral particles were pelleted on a 25% sucrose gradient using
Optima LE-80K (Beckman Coulter, Switzerland). Concentrated
viral particles were added to target cells and transduction
efficiency was assayed by FACS (BD FACSCalibur) of the
fluorescence transgenes.
Fluorescence microscopy
HEK293 and HCT116 cells were cultured in ibidi m-Plate 96
wells (ibidi, Germany). Cells were treated with LiCl or transfected
with pcDNA3-S33Y as described previously and live cells were
imaged by fluorescence microscopy (Cell Observer, Carl Zeiss,
Germany).
Prediction of transcription factor binding sites
The web base tool Transcription Element Search System
(TESS) was used to predict transcription factor binding sites
(http://www.cbil.upenn.edu/cgi-bin/tess/tess) [26].
Data analysis
Robust multi-array averaging (RMA) and quantile normaliza-
tion were used to quantify gene expression. Significant differences
were identified applying a Bayesian approach using the limma
package (R 2.12.0, Bioconductor 2.7). A threshold of an adjusted P
value #0.05 was used to identify significant changes if not
indicated otherwise. Prototype-based Gene Coexpression (PGC)
was performed as described earlier using the expO data set
GSE2109 [27]. Gene set enrichment analysis (GSEA) was carried
out according to Subramanian et al. [28] and p values were
computed using a bootstrap distribution created by resampling
gene sets of the same cardinality. The gene sets were defined as
follows: direct Wnt targets: see [29], others: see MiSigDB, http://
www.broadinstitute.org/gsea/msigdb/index.jsp), only signatures
whose name contained either ‘‘WNT’’ or ‘‘CTNNB1’’ and p
values ,0.01 were considered. Effects of signatures on overall and
recurrence free survival were studied using the Kaplan-Meier
survival curves and log rank tests in three different publicly
available data sets (GSE12945, GSE14333, GSE17537) using the
survival package in the statistical software R version 2.13.0. Patient
samples were divided into two groups splitting at the average
score. Significant differences of microarray and qRT-PCR data
were determined using a Student’s t-test, Mann_Whitney U, or
Kruskal-Wallis with Bonferroni correction depending on the data
structure and the number of groups (p value #0.05). In general,
genomics data are shown as Box-and-Whisker Plots, i.e. depicting
the smallest observation (sample minimum), lower quartile,
median, upper quartile, and largest observation (sample maxi-
mum). Correlation coefficients of relative expression levels of single
direct Wnt targets with mean expression of all targets was
performed in the panel of 967 cell lines (GSE36133). The relative
expression across cell lines was determined by gene-wise zero-
centering of expression values (Details see [21]).
Publicly available data set
Publicly available data was obtained at http://www.ncbi.nlm.
nih.gov/geo/through the accession numbers GSE2109 (expO
data), GSE5209, GSE10780, GSE21422, GSE22544, GSE3744,
GSE5764, GSE6791, GSE15960, GSE23878, GSE3029,
GSE4183, GSE15960, GSE4183, GSE11151, GSE14762,
GSE11151, GSE19188, GSE17951, GSE3325, GSE12945,
GSE14333 and GSE17537, GSE36133, GSE9452, GSE11223.
Results
FOXQ1 is over-expressed in CRCs at all stages and grades
The mRNA level of FOXQ1 has been shown to be induced in
colon adenoma and carcinoma samples [17,30]. To verify this, our
own and publicly available microarray data set of CRC samples
were examined for FOXQ1 expression and showed that FOXQ1
Table 1. FOXQ1 expression in tumor samples.
Tissue Data set Sample# Rank log2 FC log2 AS adj. p
Colon GSE30292 T = 3, N = 3 1 5.55 9.09 0.02
Colon GSE23878 T = 35, N = 24 1 4.12 7.62 0.00
Colon GSE15960 T = 6, N = 6 1 6.67 8.59 0.00
Colon GSE15960 A= 6, N = 6 5 3.33 8.59 0.00
Colon GSE4183 T = 15, N = 15 34 2.38 9.52 0.00
Breast GSE5764 T_L = 5, N_L = 10 13013 20.07 5.63 0.99
Breast GSE5764 T_D= 5, N_D= 10 13475 20.11 5.63 0.98
Breast GSE3744 T_B= 18, N= 7 1655 0.76 5.98 0.10
Breast GSE3744 T_NB= 20, N = 7 13078 20.09 5.98 0.89
Breast GSE3744 T_B= 18, T_NB= 20 709 0.86 5.98 0.01
Breast GSE21422 T = 5,N = 5 18087 20.19 5.18 0.77
Breast GSE22544 T = 14, N = 4 856 1.15 5.04 0.14
Breast GSE10780 T = 22, N = 25 17432 20.38 5.69 0.04
Cervix GSE6791 T = 20, N = 8 15532 20.33 11.07 0.52
Kidney GSE11151 T = 26,N = 3 20074 21.29 8.77 0.34
Kidney GSE14762 T = 10, N = 11 20249 21.47 8.66 0.00
Lung GSE19188 T = 47,N = 40 13409 20.04 8.28 0.93
Prostate GSE3325 T = 7, N = 6 20768 21.71 7.17 0.00
Prostate GSE17951 T = 23, N = 23 19693 20.84 10.52 0.03
FOXQ1 belongs to the most overexpressed genes in human colon adenoma
and carcinoma as compared to normal tissue. Rank orders, fold changes (FC)
and average intensity signals (AS) of FOXQ1 expression in various solid tumors
generated with GeneChipH Human Genome U133 Plus 2.0. A = adenoma,
T = tumor carcinoma, N= normal, B = basal, NB =non-basal, D =ductal,
L = lobular. Fold changes and rank orders in CRC were corroborated by data
mining of TCGA dataset (http://cancergenome.nih.gov) and others in Oncomine
(www.oncomine.org).
doi:10.1371/journal.pone.0060051.t001
Figure 1. FOXQ1 is induced on protein level in human colon
carcinoma as compared to normal tissue. Western blot analysis of
FOXQ1 in human CRC biopsy samples from three different patients.
GAPDH was used as loading control. T = tumor tissue, N =normal colon
tissue.
doi:10.1371/journal.pone.0060051.g001
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always ranked in the top of all genes being induced in CRC
(Table 1). FOXQ1 was also significantly induced on the protein
level as compared to normal tissue (Figure 1). Stratifying CRC
biopsy samples based on tumor stage, grade, localization and
metastatic status revealed no significant differences of FOXQ1
expression level (Figure 2, Figure S1). Overall and recurrence free
survival were not changed in CRC patients based on FOXQ1
expression (data not shown). Analysis of expression data from
other solid tumors showed that FOXQ1 mRNA level was not
significantly induced as compared to normal tissue (Table 1).
Overall comparison in different tumor tissues of the expO data,
the NCI60 cell line panel and a panel of 967 cell lines revealed that
FOXQ1 median expression was highest in CRC compared to all
other solid tumors (Figure S2, Figure S3, and Figure S4).
Next, we wanted to elucidate the localization of FOXQ1
expressing cells within the primary tumor (details see [21]).
Microarray and qRT-PCR analysis of laser-dissected CRC
biopsies showed that FOXQ1 was significantly overexpressed in
tumor epithelium and reactive stroma tissue (Figure 3). To exclude
that FOXQ1 over-expression in CRC samples was not due to
increased inflammation we examined FOXQ1 mRNA levels in
inflamed colon tissue. FOXQ1 was only very weakly induced in
inflamed colon tissue as compared to normal tissue (i.e. 1.2 to 3.3.
Figure 2. FOXQ1 expression is not influenced by stage, grade and localization of the tumor. Boxplots of FOXQ1 mRNA expression levels
(i.e. normalized, log2 transformed fluorescence signals) in the GSE2109 data set. Dukes Stages: stage A, B, C and D; Grades: grades 1, 2, 3 and 4;
Localization: C = colon, A = ascending colon, S = sigmoid colon, RS = recto-sigmoid, R = rectum and CE= cecum. Metastasis: non-metastatic = no
metastatic site observed, metastatic =metastatic site observed.
doi:10.1371/journal.pone.0060051.g002
Figure 3. FOXQ1 is expressed in tumor cells and reactive stroma. Boxplot of FOXQ1 mRNA levels in laser dissected human CRC samples
measured by microarray n = 3 and qRT-PCR n=3–5. TC = tumor cells, NEC= normal epithelial cells, NS =normal stroma, i.e. stromal tissue surrounding
normal colonocytes, RS = reactive stroma, i.e. stromal tissue with increased infiltration of inflammatory cells surrounding tumor cells, F = primary cells
cultures of fibroblasts and CAF= cancer-associated fibroblasts.
doi:10.1371/journal.pone.0060051.g003
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fold induction as measured in data sets GSE11223 and GSE9452,
respectively).
Association of signalling pathways with FOXQ1
As FOXQ1 was induced in CRC we wanted to test if it was
associated with Wnt signalling and/or proliferative activity in
CRC. Correlation studies (i.e. PGC) using expO data of CRC
samples revealed a strong positive correlation of FOXQ1
expression with direct Wnt targets (AXIN2, APCDD1), epithelial
marker (CDH1), intestinal stem cell marker (LGR5) and
proliferation-related genes (MKI69, TPX2, AURKA), yet a
negative correlation was observed with EMT-markers (VIM,
SNAI2, ZEB2, CDH2) (Table S2). GSEA confirmed a significant
association between FOXQ1 and direct Wnt targets and gene sets
of the MSigDB related to Wnt activation in CRC (Table 2).
In order to validate the in silico analysis, we knocked down
FOXQ1, using shRNA interference, and analysed the expression
of genes which strongly correlated with FOXQ1 expression in
colon cancer biopsy samples and EMT-related genes, which did
not correlate with FOXQ1. Knock down of FOXQ1 showed no
significant reduction on protein level (data not shown) but yielded
a 1.9 and 2.8 fold reduction of FOXQ1 mRNA levels in SW480
CRC cells (Table S3). Despite the weak knock down efficiency the
expression levels were reduced in 14 out of 17 genes whose
expression was highly correlated with FOXQ1. However the
expression of EMT related genes were not altered (Table S3) thus
corroborating the in silico data.
Table 2. Correlation of FOXQ1 with the Wnt pathway.
Tissue Direct WNT Targets SIZE ES NOM p-val FDR q-val
ALL WNT 24 0.793 0.000 0.018
Breast WNT 24 0.756 0.000 0.002
Colon WNT 24 0.723 0.000 0.000
Lung WNT 24 0.546 0.002 0.008
Pancreas WNT 24 0.535 0.006 0.022
Prostate WNT 24 0.427 0.086 0.068
Tissue MSigDB Gene Sets SIZE ES NOM p-val FDR q-val
ALL LIN_WNT_UP 49 0.702 0.001 0.397
ALL WNT_TARGETS 22 0.738 0.002 0.120
ALL WNT_SIGNALING 59 0.533 0.008 0.036
ALL WNTPATHWAY 23 0.616 0.000 0.030
ALL KENNY_CTNNB1_TARGETS_UP 45 0.481 0.008 0.031
ALL ST_WNT_BETA_CATENIN_PATHWAY 31 0.508 0.010 0.034
ALL CTNNB1_ONCOGENIC_SIGNATURE 67 0.728 0.000 0.077
Breast WNT_TARGETS 22 0.613 0.000 0.263
Breast CTNNB1_ONCOGENIC_SIGNATURE 67 0.534 0.000 0.430
Colon LIN_WNT_UP 49 0.588 0.000 0.006
Colon WNT_TARGETS 22 0.676 0.002 0.009
Colon WNT_SIGNALING 59 0.471 0.003 0.022
Colon HSA04310_WNT_SIGNALING_PATHWAY 145 0.389 0.003 0.037
Colon CTNNB1_ONCOGENIC_SIGNATURE 67 0.532 0.000 0.009
Lung LIN_WNT_UP 49 0.606 0.003 0.020
Lung KENNY_CTNNB1_TARGETS_UP 45 0.560 0.002 0.015
Lung KENNY_CTNNB1_TARGETS_DN 39 0.504 0.003 0.013
Lung WNT_SIGNALING 59 0.455 0.005 0.013
Lung WNT_TARGETS 22 0.572 0.005 0.013
Lung CTNNB1_ONCOGENIC_SIGNATURE 67 0.614 0.000 0.021
Pancreas WNT_TARGETS 22 0.585 0.002 0.038
Pancreas LIN_WNT_UP 49 0.459 0.000 0.042
Pancreas CTNNB1_ONCOGENIC_SIGNATURE 67 0.658 0.002 0.193
Pancreas LIN_WNT_UP 49 0.480 0.007 0.053
Pancreas KENNY_CTNNB1_TARGETS_DN 39 0.492 0.009 0.051
Pancreas CTNNB1_ONCOGENIC_SIGNATURE 67 0.686 0.000 0.035
Gene set enrichment analysis of FOXQ1 with a selection of gene set related to Wnt signalling. GSEA preformed in various solid tumors showed a significant enrichment
when using direct Wnt targets and gene sets related to Wnt activation. SIZE = size of tested gene set, ES = enrichment score, NOM p-val =Nominal p-value, FDR q-
val = false discovery rate q-value.
doi:10.1371/journal.pone.0060051.t002
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FOXQ1 expression is regulated by the Wnt pathway
Next, we wanted to test if the expression of FOXQ1 could be
linked with Wnt activity of CRC cell lines. Hence, the expression
of FOXQ1 was measured in a wide panel of CRC cell lines with
different Wnt activity [21,31]. A correlation was observed between
the relative FOXQ1 mRNA and protein expression with the
ranking of cell lines according to their Wnt signature expression
(Figure 4). Additional evidence for a possible regulation of
FOXQ1 through the Wnt pathway was obtained in Caco-2 cells,
where FOXQ1 upregulation was observed upon loss of CDX2
expression (Table 3). CDX2 has been shown to inhibit Wnt
signalling in Caco-2 cells [32]. Both HEK293 and the CRC cell
line HCT116 have an intact Wnt pathway and overall low Wnt
signature strength. Activation of the canonical Wnt pathway with
a small molecular GSK-3 inhibitor (LiCl) or by introducing a
constitutively active form of ß-catenin (S33Y) led to increases in
FOXQ1 mRNA and protein level (Figure 5A–5B) [22–24]. The
Wnt sensitive reporter 7TGC [25] was used to show that LiCl and
ß-catenin (S33Y) treatment activated the canonical Wnt pathway
(Figure 5C).
ß-catenin directly regulates transcription of FOXQ1
In order to investigate whether ß-catenin directly drives
transcription of FOXQ1, a 2.5 kb region upstream of the
transcription start site (TSS) of the FOXQ1 gene was analysed
for the existence of TCF4 binding sites using Transcription
Element Search System (TESS). The presence of a highly
conserved TCF4 binding site was found -1.634 kb upstream of
the TSS with a core TCF-4 binding motif (TCAAAG) [33,34]. To
demonstrate that ß-catenin was directly bound to the promoter
region of FOXQ1 we conducted ChIP experiments in the CRC
cell line SW480 which have a strong Wnt signalling activity [31].
An anti-ß-catenin antibody specifically enriched fragments of the
FOXQ1 promoter region that contained the putative TCF-4
binding site compared to IgG antibody control (Figure 6A).
Luciferase reporter assays showed that activation of the Wnt
pathway increased transcriptional activity of the wildtype FOXQ1
promoter. Mutation of the TCF-4 binding site TCAAAG to
TCAGCG (Figure 6B) resulted in a significantly decreased signal
upon Wnt activation although not a complete abrogation
(Figure 6C), thus showing that the Wnt pathway regulates
FOXQ1 expression in part via the identified TCF-4 binding site.
FOXQ1 as marker for Wnt activation in solid tumors of
different tissue origins
Activation of the Wnt pathway is a well-defined hallmark in
CRC, however, studies suggest its importance in tumor progres-
sion of other epithelial tissues such breast, lung, prostate and
pancreas [8,10,11,35–37]. Therefore, we wanted to investigate the
potential of FOXQ1 as a marker to assess Wnt activation in other
tumors. PGC using expO data revealed that breast, prostate and
colon tumors had a strong association between FOXQ1 and Wnt
related genes (t values.3 for AXIN2 and APCCD1) (Table S2).
GSEA of direct Wnt targets and genes related to Wnt activation
showed a strong positive enrichment in colon, breast, lung and
pancreas (Table 2). Moreover, we wanted to elucidate to which
extent FOXQ1 could serve as marker to assess Wnt activation in in
vitro models. Out of the direct 24 direct Wnt targets studied,
expression levels of FOXQ1, FOSL1 and CCND1 correlated best
with the mean expression of all direct Wnt targets across a panel of
967 cell lines of different tissues (Figure 7). Focusing on carcinoma
cell lines derived from colon, breast, lung, pancreas and stomach
FOXQ1 ranked best in terms of correlation with the mean
expression of all Wnt targets suggesting it to be a suitable and
sensitive marker for Wnt activation in cell lines (Figure 7).
Figure 4. FOXQ1 expression correlates with overall expression
strength of direct Wnt target in CRC cell lines. (A) FOXQ1 mRNA
levels were measured by qRT-PCR in a panel of CRC cell lines. Numbers
indicate ranks in terms of Wnt signalling strength according to
Christensen et al. [21], with rank 1 having the strongest mean Wnt
signal strength. (B) Western blot of selected CRC cell lines showing the
expression level of FOXQ1. Tubulin was used as loading control.
doi:10.1371/journal.pone.0060051.g004
Table 3. Regulation of FOXQ1 expression upon loss of CDX2
expression.
Sample Name CDX2 AXIN2 FOXQ1
sh1_5days 21.2 2.5 3.7
sh2_5days 21.2 2.0 2.5
sh3_5days 21.4 2.1 2.2
sh1_3weeks 21.8 2.3 3.2
sh2_3weeks 21.6 1.3 2.4
sh3_3weeks 21.5 1.8 2.3
Relative expression levels (fold changes) of CDX2, FOXQ1 and AXIN2 in shCDX2
Caco-2 cells grown for 5 days and 3 weeks as compared to control transfected
cells, measured by qRT-PCR.
doi:10.1371/journal.pone.0060051.t003
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Figure 5. Activation of the Wnt pathway leads to increased FOXQ1 expression. (A) qRT-PCR analysis of FOXQ1 expression in HEK293 and
HCT116 cell lines after Wnt activation. Cell were treated with 20 mM LiCl for 24 hours or transfected with a constitutively active form of ß-catenin
(S33Y). Data are mean 6 SD n= 3, **P,0.01 using Mann-Whitney test. (B) Western blot of FOXQ1 in HEK293 and HCT116 after Wnt activation as
described above. GAPDH was used a loading control. (C) HEK293 and HCT116 cells stably expressing the Wnt sensitive reporter 7TGC [25] were
treated as described above and imaged. GFP (green) is under the control of a Wnt sensitive promoter and mCherry (red) is constitutively expressed to
identify infected cells, white bar indicates 20 mm.
doi:10.1371/journal.pone.0060051.g005
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Discussion
In this study, using microarray data from cancer cell lines and
patient samples, and molecular biological techniques we examined
the relationship between FOXQ1 and the Wnt pathway. FOXQ1
expression was highly correlated with the activity of the Wnt
pathway in primary tumors and cell lines of epithelial origin.
FOXQ1 mRNA and protein levels could be increased by
activating of the canonical Wnt pathway via LiCl or by
introduction of a constitutively active form of ß-catenin (S33Y).
ß-catenin was bound to the promoter region of FOXQ1 at a
highly conserved TCF-4 binding site. The wildtype promoter
region was transcriptional active when the Wnt pathway was
activated. Mutation of the TCF-4 binding decreased the
transcriptional activity of the promoter upon Wnt activation.
Recent reports have shown that FOXQ1 was upregulated in
CRC, metastatic breast cancer cell lines and FOXQ1 expression
level in lung and breast cancer patients was highly correlated with
EMT markers [17–19,38] However, in CRC, FOXQ1 expression
was independent of grade, location and metastasis (Figure 2,
Figure S1), despite being among the most upregulated genes in
CRC (Table 1). FOXQ1 overexpression did not influence overall
or recurrence free survival in CRC patients; this is in contrast to
data from breast and lung cancer patients where FOXQ1 was
associated with worse survival [18,38]. Also, in contrast to findings
in breast cancer we could not observe an association of FOXQ1
with EMT features in CRC (Table S2, Table S3 and Table S4).
Interestingly, no association was found between Wnt signalling
and EMT features in CRC (data not shown). Contribution of Wnt
activation to tumorigenesis may vary depending on the tissue of
origin. Wnt activation is an early and frequent event in CRC
owing to mutations of various genes in the Wnt signalling cascade
[7]. This results in an initial increase of basal Wnt activity in the
tumors. In contrast, increased Wnt signalling in breast and lung
tumors are most likely due to external cues rather than mutation
[39,40]. Also, Wnt activation is a later event that is associated with
tumor progression and a more invasive phenotype [8,10,36].
The Wnt pathway is emerging as an important regulator of
various cancer hallmarks and as a prognostic tool. ß-catenin
staining is the standard for analysing Wnt activation but mRNA
analysis techniques such as qRT-PCR and microarray are
important tools in basic and clinical research. It is important to
have reliable mRNA markers for Wnt activation that can be
analysed in different tissues. Compared to 24 previously known
Wnt targets FOXQ1 expression level was one of the best markers
for assessing Wnt activity in a panel of 967 cell lines derived from
different tissues. Also in primary tumors FOXQ1 correlated with
signatures related to the Wnt pathway. This data indicates that
FOXQ1 could potentially be used as a Wnt marker in multiple
tissues.
In summary, we showed for the first time the molecular events
underpinning the increased expression of FOXQ1 in cancers, and
Figure 6. ß-catenin binds to the promoter region of FOXQ1 and increase transcription. (A) ChIP assay was performed on SW480 cells with
antibodies against ß-catenin and IgG (control). Input and immunoprecipitated DNA was measured by qRT-PCR using primers amplifying the
promoter region of FOXQ1 and the 2100/0 promoter region of GAPDH. Data are mean6 SD n=3, **P,0.01 using Mann-Whitney test. (B) Graphical
depiction of the promoter region of FOXQ1, and the generated promoter reporter vectors. (C) Luciferase assay showing the effect of Wnt activation
in HEK293 and HCT116 cells (as described in figure 5) transfected with the wild type promoter region of FOXQ1 (pGL3_FOXQ1_WT), a mutated TCF4
binding site (pLG3_FOXQ1_Mut) or an empty vector (pGL3_Emtpy). Data are mean6 SD n= 4–7, *P,0.05, ***P,0.001 by the Kruskal-Wallis Conover
test.
doi:10.1371/journal.pone.0060051.g006
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show the usefulness of FOXQ1 as a marker for Wnt activity in
cancer cell lines.
Supporting Information
Figure S1 FOXQ1 expression is not influenced by stage,
grade and localization of the tumor. Boxplots of FOXQ1
mRNA expression levels (i.e. normalized, log2 transformed
fluorescence signals) in the GSE5206 data set. Stages: stage A,
B, C and D; Grades: well =well differentiated, mod=moderately
differentiated and poorly = poorly differentiated; Localization:
S= sigmoid colon, A= ascending colon, CE= cecum, R= rectum,
T= transverse colon and D=descending. Metastasis: non-metas-
tatic = no metastatic site observed and metastatic =metastatic site
observed.
(PDF)
Figure S2 FOXQ1 is highest expressed in human CRC.
Boxplots of FOXQ1 mRNA (normalized fluorescence signal
levels, log2 transformed) in human biopsy samples of various
tumors (expO data set, GSE2109). BR=breast, CO= colon,
KI= kidney, OV=ovary, UT=uterus, LU= lung, PR=prostate,
EN= endometrium, OM=omentum, LI= liver.
(PNG)
Figure S3 FOXQ1 is highest expressed in cell lines
derived from CRC. Boxplots of FOXQ1 mRNA expression
level (normalized fluorescence signal levels, log2 transformed) in
the NCI60 cell line panel. BR=breast, CNS= central nervous
system, CO= colon, LC= lung, LE= leukocytes, ME=mela-
noma, OV=ovarian, PR=prostrate, RE= rectum
(PDF)
Figure S4 Expression of Wnt targets and FOXQ1 in a
wide panel of cancer derived cell lines. Boxplots of FOXQ1
mRNA expression level (normalized fluorescence signal levels,
log2 transformed), and direct Wnt targets CCND1, FOSL1 and
AXIN2 [log2 transformed] in 967 cancer cell lines derived from
different tissues (GSE36133).
(PDF)
Table S1 Primers sequences for Real-Time PCR.
(DOCX)
Table S2 Strong association of FOXQ1 expression with
genes involved in Wnt signaling and proliferation. T-
statistics based on Prototype-based Gene Coexpression analysis
(expO data set (GSE2109)) with respect to the correlation of
FOXQ1 with various known direct Wnt targets (AXIN2,
APCDD1), markers for proliferation (MKI67, TPX2, AURKA),
mesenchymal cells/EMT (VIM, SNAI1, ZEB2, CDH2), differen-
tiated epithelial cells (CDH1) and intestinal stem cells (LGR5).
(DOCX)
Table S3 Confirmation of in silico analysis. FOXQ1 was
knocked down in SW480 cells using two different shRNA
constructs (KD1 and KD2). The relative expression levels (fold
changes) of genes strongly correlating with FOXQ1 expression in
human colon cancer biopsy samples and or genes associated
involved in EMT were measured using qRT-PCR. Data is shown
as fold changes compared to wild type SW480. T-statistics based
on Prototype-based Gene Coexpression analysis of FOXQ1 using
the expO data set (GSE2109).
(DOCX)
Table S4 Significant enrichment of direct EMT-related
genes targets in tumors. Gene set enrichment analysis with an
EMT-related gene set (see [29]).
(DOCX)
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